R, Formstecher E, Roland C, Cheng T et al. TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation. Mol Cell 2011; 41: 45870. 25. Xie X, Zhang D, Zhao B, Lu MK, You M, Condorelli G et al. IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation. Proc Natl Acad Sci USA 2011; 108: 6474479. 26. Guo JP, Coppola D, Cheng JQ. IKBKE protein activates Akt independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 plus the pleckstrin homology domain to sustain malignant transformation. J Biol Chem 2011; 286: 373897398. 27. Gatot JS, Gioia R, Chau TL, Patrascu F, Warnier M, Close P et al. Lipopolysaccharidemediated interferon regulatory aspect activation requires TBK1-IKKepsilon-dependent Lys(63)-linked polyubiquitination and phosphorylation of TANK/I-TRAF. J Biol Chem 2007; 282: 311311146. 28. Fujita F, Taniguchi Y, Kato T, Narita Y, Furuya A, Ogawa T et al. Identification of NAP1, a regulatory subunit of I kappa B kinase-related kinases that potentiates NF-kappa B signaling. Mol Cell Biol 2003; 23: 7780793. 29. Pomerantz JL, Baltimore D. NF-kappa B activation by a signaling complex containing TRAF2, TANK and TBK1, a novel IKK-related kinase. Embo J 1999; 18: 6694704. 30. Yamaoka S, Courtois G, Bessia C, Whiteside ST, Weil R, Agou F et al. Complementation cloning of NEMO, a element of your IkappaB kinase complex essential for NF-kappaB activation. Cell 1998; 93: 1231240. 31. Rae JM, Johnson MD, Scheys JO, Cordero KE, Larios JM, Lippman ME. GREB 1 is usually a crucial regulator of hormone dependent breast cancer growth. Breast Cancer Res Treat 2005; 92: 14149. 32. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 2001; 276: 9817824. 33. Keutgens A, Shostak K, Close P, Zhang X, Hennuy B, Aussems M et al. The Repressing Function of the Oncoprotein BCL-3 Calls for CtBP, when Its Polyubiquitination and Degradation Involve the E3 Ligase TBLR1. Mol Cell Biol 2010; 30: 4006021.Onvansertib 34. Duong V, Boulle N, Daujat S, Chauvet J, Bonnet S, Neel H et al. Differential regulation of estrogen receptor alpha turnover and transactivation by Mdm2 and stress-inducing agents. Cancer Res 2007; 67: 5513521. 35. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation with the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 84448. 36. Patel S, Player MR. Small-molecule inhibitors in the p53-HDM2 interaction for the remedy of cancer. Professional Opin Invest Drugs 2008; 17: 1865882. 37. Mendrysa SM, McElwee MK, Michalowski J, O’Leary KA, Young KM, Perry ME.Sulfasalazine mdm2 Is crucial for inhibition of p53 through lymphopoiesis as well as the response to ionizing irradiation.PMID:22943596 Mol Cell Biol 2003; 23: 46272. 38. Callige M, Richard-Foy H. Ligand-induced estrogen receptor alpha degradation by the proteasome: new actors Nucl Recept signal 2006; four: e004. 39. Close P, Hawkes N, Cornez I, Creppe C, Lambert CA, Rogister B et al. Transcription impairment and cell migration defects in elongator-depleted cells: implication for familial dysautonomia. Mol cell 2006; 22: 52131. 40. Viatour P, Dejardin E, Warnier M, Lair F, Claudio E, Bureau F et al. GSK3-mediated BCL-3 phosphorylation modulates its degradation and its oncogenicity. Mol cell 2004; 16: 355. 41. Chariot A, Leonardi A, Muller J, Bonif M, Brown K, Siebenlist U. Association of the ada.
